This single arm study will assess the safety and efficacy of Tarceva monotherapy in patients with advanced non-small cell lung cancer. Patients will receive Tarceva 150mg p.o. daily. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
5
150mg po daily
Unnamed facility
Balashikha, Russia
Unnamed facility
Krasnoyarsk, Russia
Incidence of adverse events (AEs)
Time frame: Length of patient on study (length of time of patient on study determined by investigator)
Best Response Rate per investigator assessment
Time frame: Length of patient on study (length of time of patient on study determined by investigator)
Time to Progression (TTP)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first
Overall survival
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.